+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A new concept of antidepressant drugs action: clinical and preclinical data



A new concept of antidepressant drugs action: clinical and preclinical data



Psychiatria Polska 28(1): 39-50



The authors propose a new concept of antidepressant drug action based on adaptive receptor changes occurring in the course of chronic antidepressant treatment. Some clinical data and more equivocally preclinical studies indicate an enhancement of activity of those neurotransmitter systems which exert an activating impact on diverse cns functions (dopaminergic and alpha-1 adrenergic receptors). On the other hand the same treatment is found to inhibit the activity of central inhibitory systems (e.g. serotonergic and GABAergic receptors), thus resulting in an increase of positive reinforcement and psychomotor processes in the cns.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 045079656

Download citation: RISBibTeXText

PMID: 7910691


Related references

Clinical data on the role of serotonin in the mechanism(s) of action of antidepressant drugs. Journal of Clinical Psychiatry 51 Suppl: 44-50; Discussion 51-2, 1990

New Concept of the Anticholinergic Mechanism of the Action of Antidepressant Thymoleptic Drugs. Postepy Higieny i Medycyny Doswiadczalnej 18: 925-944, 1964

The serotonin concept of depression in light of the mechanism of action of antidepressant drugs. Psychiatria Polska 23(2): 117-124, 1989

Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacology and Therapeutics 145: 43-57, 2015

Why do antidepressant drugs show a delayed onset of clinical action?. Pharmacopsychiatry 30(5): 164, 1997

The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. Journal of Clinical Psychiatry 69(10): 1513-1528, 2008

The use of clinical kinetic data in treatment with antidepressant drugs. Acta Psychiatrica Scandinavica. Supplementum 280: 157-167, 1980

Temperature dependence of the action of cytostatic drugs Preclinical and clinical studies. Journal of Cancer Research & Clinical Oncology 120(Suppl. ): R80, 1994

Investigational drugs for fracture healing: preclinical & clinical data. Expert Opinion on Investigational Drugs 25(5): 585-596, 2016

Antidepressant drugs and seizure susceptibility: From in vitro data to clinical practice. Epilepsia 40(Suppl. 10): S48-S56, 1999

Antidepressant drugs in children and adolescents: analytical and demographic data in a naturalistic, clinical study. Journal of Clinical Psychopharmacology 31(1): 98, 2011

European Drug Guideline Series 1, 2, 3 and 6: Guidelines for the Clinical Investigation of Neuroleptic Drugs, Anxiolytic Drugs, Hypnotic Drugs and Antidepressant Drugs. International Clinical Psychopharmacology 1(3): 267-268, 1986

In Vitro/In Vivo bone Marrow Toxicity Comparison of Clinical and Preclinical Data for Selected Anticancer Drugs. Proceedings of the American Association for Cancer Research Annual Meeting 36: 367, 1995

Oxaliplatin Preclinical mechanism of action and preclinical data. European Journal of Cancer 33(Suppl. 2): S3-S7, 1997

From antidepressant drugs to beta-mimetics: preclinical insights on potential new treatments for neuropathic pain. Recent Patents on Cns Drug Discovery 4(3): 182-189, 2009